Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback

 
• By Joseph Haas

The Phase III failure of ampreloxetine in nOH followed disappointing Phase IIb data for izencitinib in ulcerative colitis in August. Theravance narrows focus to respiratory disease, including label expansions for Yupelri.

Business reengineering
Theravance will try an overhaul focused on respiratory disease to stay viable

More from Strategy

More from Business